NasdaqGM - Nasdaq Real Time Price USD
Intellia Therapeutics, Inc. (NTLA)
7.80
+0.13
+(1.76%)
As of 1:35:06 PM EDT. Market Open.
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 364,539 | 10 |
| Sales | 72,037 | 11 |
| Net Shares Purchased (Sold) | 292,502 | 21 |
| Total Insider Shares Held | 5.14M | -- |
| % Net Shares Purchased (Sold) | 6.00% | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| BHANJI MUNA Director | Sale at price 8.50 per share. | Direct | 2,252 | Apr 29, 2025 |
| BASTA JAMES EDMUND General Counsel | Sale at price 8.99 per share. | Direct | 23,122 | Mar 4, 2025 |
| CLARK ELIANA Chief Technology Officer | Sale at price 8.99 per share. | Direct | 6,104 | Mar 4, 2025 |
| DUBE MICHAEL P Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 28, 2025 |
| LEONARD JOHN M Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 28, 2025 |
| BASTA JAMES EDMUND General Counsel | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 28, 2025 |
| LEBWOHL DAVID Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 28, 2025 |
| DULAC EDWARD J III Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 28, 2025 |
| CLARK ELIANA Chief Technology Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 28, 2025 |
| BHANJI MUNA Director | Sale at price 9.97 per share. | Direct | 2,642 | Jan 29, 2025 |
| SEPP-LORENZINO LAURA Officer | Sale at price 12.18 per share. | Direct | 109,206 | Jan 3, 2025 |
| BASTA JAMES EDMUND General Counsel | Sale at price 12.18 per share. | Direct | 86,161 | Jan 3, 2025 |
| LEBWOHL DAVID Officer | Sale at price 12.18 per share. | Direct | 116,404 | Jan 3, 2025 |
| HICKS DEREK Officer | Sale at price 12.18 per share. | Direct | 79,194 | Jan 3, 2025 |
| CLARK ELIANA Chief Technology Officer | Sale at price 12.03 - 12.18 per share. | Direct | 97,089 | Jan 3, 2025 |
| DUBE MICHAEL P Officer | Sale at price 12.18 per share. | Direct | 16,711 | Jan 3, 2025 |
| LEONARD JOHN M Chief Executive Officer | Sale at price 12.18 per share. | Direct | 326,509 | Jan 3, 2025 |
| LEBWOHL DAVID Officer | -- | Direct | -- | Dec 31, 2024 |
| LEONARD JOHN M Chief Executive Officer | -- | Direct | -- | Dec 31, 2024 |
| SEPP-LORENZINO LAURA Officer | -- | Direct | -- | Dec 31, 2024 |
| DUBE MICHAEL P Officer | Sale at price 19.01 per share. | Direct | 38,248 | Oct 2, 2024 |
| DULAC EDWARD J III Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jul 22, 2024 |
| DUBE MICHAEL P Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jul 1, 2024 |
| CLARK ELIANA Chief Technology Officer | Sale at price 22.93 per share. | Direct | 9,287 | Jul 1, 2024 |
| VERWIEL FRANK Director | Sale at price 25.00 per share. | Direct | 37,625 | Jun 17, 2024 |
| GOFF BRIAN M Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jun 13, 2024 |
| COHEN FREDERICK E. M.D. PH.D. Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jun 12, 2024 |
| VERWIEL FRANK Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jun 12, 2024 |
| CHASE WILLIAM J Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jun 12, 2024 |
| GOODMAN JESSE Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jun 12, 2024 |
| KERESTY GEORGIA Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jun 12, 2024 |
| BHANJI MUNA Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jun 12, 2024 |
| BASTA JAMES EDMUND General Counsel | Sale at price 32.99 per share. | Direct | 75,778 | Mar 4, 2024 |
| CLARK ELIANA Chief Technology Officer | Sale at price 32.99 per share. | Direct | 19,959 | Mar 4, 2024 |
| LEONARD JOHN M Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Mar 1, 2024 |
| GODDARD GLENN G Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Mar 1, 2024 |
| SEPP-LORENZINO LAURA Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Mar 1, 2024 |
| BASTA JAMES EDMUND General Counsel | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Mar 1, 2024 |
| LEBWOHL DAVID Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Mar 1, 2024 |
| HICKS DEREK Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Mar 1, 2024 |
| CLARK ELIANA Chief Technology Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Mar 1, 2024 |
| SEPP-LORENZINO LAURA Officer | Sale at price 28.66 - 29.38 per share. | Direct | 65,682 | Jan 8, 2024 |
| SEPP-LORENZINO LAURA Officer | Sale at price 29.46 per share. | Direct | 162,973 | Jan 3, 2024 |
| BASTA JAMES EDMUND General Counsel | Sale at price 29.46 per share. | Direct | 112,095 | Jan 3, 2024 |
| LEBWOHL DAVID Officer | Sale at price 29.46 per share. | Direct | 172,135 | Jan 3, 2024 |
| HICKS DEREK Officer | Sale at price 29.46 per share. | Direct | 114,216 | Jan 3, 2024 |
| CLARK ELIANA Chief Technology Officer | Sale at price 29.46 - 30.12 per share. | Direct | 135,954 | Jan 3, 2024 |
| LEONARD JOHN M Chief Executive Officer | Sale at price 29.46 per share. | Direct | 566,310 | Jan 3, 2024 |
| GODDARD GLENN G Chief Financial Officer | Sale at price 29.46 per share. | Direct | 158,053 | Jan 3, 2024 |
| LEBWOHL DAVID Officer | -- | Direct | -- | Dec 29, 2023 |
Related Tickers
CRSP CRISPR Therapeutics AG
39.30
+3.29%
BEAM Beam Therapeutics Inc.
17.35
+1.14%
SMMT Summit Therapeutics Inc.
19.83
+1.38%
EDIT Editas Medicine, Inc.
1.8154
-0.25%
BPMC Blueprint Medicines Corporation
128.00
-0.08%
REGN Regeneron Pharmaceuticals, Inc.
487.18
+0.46%
VERA Vera Therapeutics, Inc.
31.74
-0.80%
KYMR Kymera Therapeutics, Inc.
47.37
+7.03%
RXRX Recursion Pharmaceuticals, Inc.
4.7000
-4.28%
VERV Verve Therapeutics, Inc.
5.99
+13.14%